MOTS-c human studies: what the research actually shows

Last updated 2026-07-24

Are there any human clinical trials on MOTS-c?

No completed, published human efficacy trial exists on PubMed as of this writing. Search the literature for MOTS-c and you'll find a lot of activity, dozens of papers going back a decade, but the human arm is essentially absent. What you get instead is a thick stack of mouse studies, cell-culture work, and a handful of review articles that speculate about human relevance. This matters because MOTS-c gets talked about online like it's a proven exercise-mimetic or anti-aging compound. It isn't proven in humans at all. A 2023 review in Frontiers in Endocrinology calls MOTS-c "a promising mitochondrial-derived peptide for therapeutic exploitation," which is accurate phrasing: promising, not demonstrated ^[1]. Promising is a hope. It is not a result. The practical takeaway for anyone evaluating MOTS-c against the hype: every specific number you'll read about fat loss, insulin sensitivity, or muscle preservation comes from a mouse, not a person. Keep that distinction in your head as you read the rest of this piece, because we're about to walk through the animal data in detail, and it's easy to forget the species halfway through a sentence full of pathway names.

What is MOTS-c and where does it come from?

MOTS-c is a 16-amino-acid peptide encoded not in your nuclear DNA but inside the mitochondrial genome, specifically in a small open reading frame within the 12S rRNA gene. That's an unusual origin. Most peptide hormones you've heard of come from nuclear genes; MOTS-c is one of a small class called mitochondrial-derived peptides (MDPs), discovered because researchers noticed the mitochondrial genome was coding for more than just the respiratory chain proteins everyone assumed it made. The foundational animal study, published in Cell Metabolism in 2015, found that MOTS-c "promotes metabolic homeostasis and reduces obesity and insulin resistance" in mice ^[2]. That's the paper nearly every subsequent MOTS-c article traces back to, and it's mouse data, not human. A later mechanistic paper, also in Cell Metabolism (2018), showed something genuinely interesting: under metabolic stress, MOTS-c translocates from the cytoplasm into the nucleus, where it regulates the expression of nuclear genes involved in antioxidant response ^[3]. A 2019 review in BioEssays frames this as MOTS-c acting as "a mitochondrial-encoded regulator of the nucleus," a two-way communication channel between mitochondria and the cell's control center ^[4]. This nuclear-translocation mechanism is one of the more solid pieces of biology here. It's still cell and mouse work, but it's a real, reproducible mechanism, not speculation.

Is MOTS-c really an 'exercise in a pill'?

The exercise-mimetic framing is a marketing shorthand, not a finding any study actually makes. What the research shows is narrower and more interesting: MOTS-c is a signaling molecule that increases in circulation and in skeletal muscle in response to exercise, and it appears to activate some of the same downstream pathways exercise activates, largely through AMPK. A 2022 review in Diabetes & Metabolism Journal, titled "Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c)," lays out this relationship ^[5]. A separate 2021 review in Biochimica et Biophysica Acta covers mitochondrial-derived peptides and exercise more broadly, again as an association and mechanism story, not a human trial of the peptide as a drug ^[6]. Here's the distinction that gets lost: showing a peptide rises during exercise and showing that giving people the isolated peptide reproduces exercise's benefits are two completely different claims. The first is reasonably well supported in animal and cell models. The second, the actual 'exercise in a pill' claim, has no human trial behind it at all. If someone sells you MOTS-c as a workout substitute, they're selling you an inference from mouse endocrinology, dressed up as a settled human fact.

What do the metabolic and diabetes studies show?

This is where MOTS-c has the deepest data, and it's still all preclinical. The original 2015 Cell Metabolism paper found MOTS-c administration reduced diet-induced obesity and improved insulin resistance in mice ^[2]. A 2022 study in Pharmacological Research extended this to a specific condition, gestational diabetes, finding MOTS-c "relieves hyperglycemia and insulin resistance" in that model ^[7]. A 2023 paper in Metabolites, titled "MOTS-c Functionally Prevents Metabolic Disorders," and a 2023 review in Diabetes & Metabolism Journal covering MOTS-c's relationship to diabetes and aging-related disease both reinforce the same picture: consistent metabolic benefit signals across multiple animal and cell models ^{[8] [9]}. A 2025 paper in Experimental & Molecular Medicine found MOTS-c "prevents pancreatic islet cell senescence to delay diabetes" in its model system ^[10]. A separate 2025 review in Cardiovascular Drugs and Therapy asks bluntly in its title whether MOTS-c is a "Magical Molecule for Diabetic Cardiomyopathy," which tells you the field's enthusiasm has outpaced its proof; the question mark in that title is doing real work ^[11]. Add it up and you get a genuinely consistent preclinical signal across independent labs and models. That consistency is worth something. It is not the same as a human dose-response trial, and nobody should tell you it is.

Does MOTS-c help with muscle, exercise recovery, or muscle loss?

The muscle data is one of the more active sub-areas and it's still animal and cell-based. A 2024 study in iScience found MOTS-c "modulates skeletal muscle function by directly binding and activating CK2," identifying a specific molecular target rather than just a downstream effect ^[13]. A 2022 paper in Peptides showed MOTS-c "promotes muscle differentiation in vitro," meaning in cultured muscle cells, not in a living organism, let alone a person ^[14]. On the atrophy side, a 2021 study in the American Journal of Physiology found MOTS-c "reduces myostatin and muscle atrophy signaling" ^[15], and a 2024 study in the same journal found MOTS-c "attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration" in an animal model ^[16]. Together these suggest a plausible mechanism for why MOTS-c gets marketed toward people worried about muscle wasting or slow recovery. A 2026 paper in Sports Medicine reviewed the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, which is a useful reality check: it's a review capturing what's approved versus what's being used off-label with thin support, and MOTS-c sits firmly in the latter category ^[17]. If you're weighing MOTS-c for recovery or muscle preservation, the honest read is: mechanistically plausible, animal-supported, human-unproven. For anyone tracking practical dosing questions once they've decided to move forward anyway, our mots-c dosage guide and the mots-c 10mg dosage calculator cover the numbers people actually ask about, separate from the efficacy question.

What about MOTS-c and cancer, is it protective or risky?

The cancer data is narrow and specific, and it points toward a tumor-suppressive role in at least one cancer type, not a general anti-cancer claim. A 2024 study in Advanced Science found MOTS-c "suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination," a specific molecular mechanism studied in an ovarian cancer model ^[18]. That's one cancer type, one mechanism, one paper. It doesn't tell you anything about breast, prostate, colon, or any other cancer, and it doesn't tell you what MOTS-c does in a healthy person's existing cell population over years of use, which is the real safety question for anyone using an unregulated peptide long-term. There is no long-term human safety data on MOTS-c at any dose, cancer-related or otherwise. Separately, older work flagged that some mitochondrial-derived peptides can influence senescence pathways in complicated ways: a 2018 paper in Rejuvenation Research titled "Mitochondrial-Derived Peptides Exacerbate Senescence" studied this family of peptides and found effects that push against the simple "MDPs are all protective" narrative ^[19]. That paper is about MDPs broadly, not MOTS-c specifically in every instance, so read it as a caution about oversimplifying the family, not a specific verdict on MOTS-c.

Does MOTS-c protect organs like the lungs, heart, and liver?

This is the largest and most surprising cluster of findings, and it's entirely mechanistic animal and cell work spanning organ systems nobody expected a 'metabolic peptide' to touch. A 2025 study in Redox Biology found MOTS-c attenuates lung ischemia-reperfusion injury through a MYH9-dependent nuclear translocation mechanism, activating antioxidant genes ^[20]. A 2023 study in European Journal of Pharmacology found MOTS-c suppresses ferroptosis (an iron-dependent cell death pathway) and reduces acute lung injury after myocardial ischemia reperfusion, via PPARγ signaling ^[21]. A 2023 paper in Mitochondrion identifies MOTS-c as a potential anti-pulmonary fibrosis factor ^[22], and a 2025 paper in International Immunopharmacology found it attenuates airway barrier dysfunction in a model of allergic asthma via the Nrf2 pathway ^[23]. On the liver side, a 2025 study in Scientific Reports found MOTS-c "mimics exercise to combat diabetic liver fibrosis by targeting Keap1-Nrf2-Smad2/3" ^[12], again in an animal model, and notably using "mimics exercise" as a mechanistic descriptor rather than a human outcome claim. A 2024 study in Gut found a genuinely unexpected role: MOTS-c participates in antiviral defense during hepatitis B virus infection through mitochondrial remodeling ^[24]. A 2025 study in the American Journal of Respiratory Cell and Molecular Biology found MOTS-c promotes glycolysis via an AMPK-HIF-1α-PFKFB3 pathway to reduce lung injury after cardiopulmonary bypass, again in an animal model ^[25]. That is a striking spread of organ systems for one small peptide to touch. It's also exactly the pattern you'd expect from a molecule that regulates a core, upstream stress-response pathway (Nrf2 antioxidant signaling shows up again and again across these papers) rather than a molecule with one narrow job. Interesting biology. Still animal and cell data across the board.

Does MOTS-c affect bone, joints, or connective tissue?

Yes, in animal and cell models, with two separate lines of evidence. A 2023 review in Frontiers in Physiology covers MOTS-c's role in bone metabolism generally ^[26]. A 2025 study in Free Radical Biology & Medicine found MOTS-c attenuates mitochondrial dysfunction, pyroptosis, and cartilage degradation in an osteoarthritis model, through an Nrf2-dependent mechanism, the same antioxidant pathway that keeps recurring across the lung and liver studies ^[27]. A more applied 2025 paper in Materials Today Bio used MOTS-c as a component of a functional peptide hydrogel to enhance stem cell activity relevant to intervertebral disc degeneration ^[28], which is a tissue-engineering application rather than a systemic drug study, worth knowing about if you're tracking where this peptide might eventually show up in regenerative medicine, but not evidence for injecting MOTS-c systemically for joint health.

Are there other unexpected uses being studied?

A few papers extend MOTS-c into areas with no obvious metabolic connection at all, which is either a sign of a genuinely central biological mechanism or a sign the field is throwing the peptide at everything to see what sticks. Probably some of both. A 2024 study in Theranostics found MOTS-c participates in plasma membrane repair by facilitating translocation of a protein called TRIM72 to the membrane, a cell-repair mechanism ^[29]. A 2026 paper in Autophagy found MOTS-c ameliorates lysosomal membrane permeability and improves survival of soft tissue transplantation in an animal model, relevant to reconstructive surgery research ^[30]. Each of these is a single study in a specific model. None has been replicated widely, and none has moved to human testing. They're worth knowing about if you're tracking the field's trajectory, but they shouldn't move your personal risk-benefit calculation much either way.

Why hasn't MOTS-c been through human clinical trials yet?

A few honest reasons, none of them exotic. First, MOTS-c is not an FDA-approved drug. It doesn't appear in the Drugs@FDA database of approved products ^[31], which means no company has taken it through the IND and Phase 1-3 pipeline that produces the kind of human data researchers actually trust. Second, MOTS-c's regulatory status as a compounded substance is unsettled and worth understanding before you consider using it. Compounding pharmacies can only use bulk drug substances that appear on FDA's 503A or 503B bulks lists, established under 21 CFR 216.23 and 216.24 ^{[32] [33]}, or substances otherwise permitted under the compounding provisions of 21 U.S.C. 353a ^[34]. FDA maintains and updates a list of bulk substances nominated for 503A compounding consideration ^[35], and MOTS-c's presence or absence on the current approved lists can change; check FDA's own bulk drug substances page for the live status rather than trusting any third-party summary, including this one ^[36]. Third, and this is the practical reason: running a real human trial costs millions of dollars and years of work, and nobody has stepped up to fund one for a peptide that isn't patentable in a way that guarantees a return. That's not a conspiracy, it's just how drug development economics work. Until someone funds Phase 1 human safety and dosing work, MOTS-c stays in this odd space: mechanistically rich, commercially available in some research-chemical and compounded forms, and clinically unproven in the species that actually matters to you.

What does the mouse-to-human evidence gap actually mean for you?

It means every specific efficacy claim you read about MOTS-c, fat loss percentages, insulin sensitivity improvements, muscle preservation numbers, comes from a mouse or a petri dish, and mice are not small humans. Metabolic pathways overlap a lot between species, which is why the mouse data is worth taking seriously as a research signal. But dose-response, half-life, off-target effects, and long-term safety in humans are simply unknown quantities right now. If you're a researcher evaluating this space, the honest position is: MOTS-c has one of the more mechanistically interesting and reproducible preclinical stories among mitochondrial peptides, spanning metabolism, muscle, multiple organ-protection contexts, and even antiviral and cancer biology. It also has zero completed human efficacy trials. Both things are true at once, and anyone who tells you only the first half is selling you something. If you're a person considering MOTS-c for personal use rather than research interest, that gap should weigh heavily. Our mots-c side effects page covers what little safety signal exists, mostly extrapolated from the animal literature and general peptide-class experience rather than dedicated human trials, and it's worth reading before anything else. For the hub overview tying all of this together, see mots-c.

If I still want to use MOTS-c, what should I know about sourcing?

Given the regulatory picture above, sourcing quality is one of the few variables you can actually control, since efficacy and long-term safety remain open questions regardless of where you buy. MOTS-c Co reviews providers against that regulatory backdrop, meaning we look at whether a source uses a pharmacy that operates within the 503A/503B compounding framework rather than an unregulated research-chemical seller with no quality oversight at all. We don't compound or manufacture anything ourselves; we evaluate and point toward provider-reviewed routes and name the pharmacy partner actually fulfilling the product, which is the detail worth checking before you hand over payment to anyone. If you're at the stage of comparing sourcing options, our mots-c peptide buy guide walks through what to check, and the mots-c peptide injection guide covers handling and administration basics separate from the efficacy question this article addresses.

Frequently asked questions

Has MOTS-c been tested in humans?

Not in a completed, published clinical efficacy trial as of this writing. PubMed's MOTS-c literature is almost entirely mouse studies and cell-culture work, plus mechanistic and review papers. No dose-response, safety, or outcomes trial in humans has been published, which is a real gap given how many metabolic and organ-protection claims circulate about this peptide.

Is MOTS-c FDA approved?

No. MOTS-c does not appear in Drugs@FDA, the database of FDA-approved drug products (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm). Its status for compounding depends on whether it appears on FDA's 503A or 503B bulk drug substance lists under 21 CFR 216.23 and 216.24, which can change, so check FDA's current bulk substances page directly.

Does MOTS-c really work like exercise in a pill?

That phrase is marketing, not a study finding. Research shows MOTS-c rises during exercise and activates some overlapping pathways (mainly AMPK), per a 2022 Diabetes & Metabolism Journal review. But no study has given isolated MOTS-c to humans and reproduced exercise's benefits; the 'pill' claim is an inference from animal endocrinology, not a demonstrated human effect.

What did the original 2015 MOTS-c study find?

The foundational 2015 Cell Metabolism paper found that MOTS-c administration reduced diet-induced obesity and improved insulin resistance in mice. It's the single most-cited MOTS-c paper and the source of most 'metabolic benefit' claims you'll see online, but it's mouse data, not a human trial.

Can MOTS-c help with muscle loss or atrophy?

Animal studies suggest it might: a 2021 study found MOTS-c reduces myostatin and muscle atrophy signaling, and a 2024 study found it attenuates immobilization-induced muscle atrophy in an animal model by suppressing lipid infiltration. Both are preclinical. No human trial has tested MOTS-c for muscle preservation or sarcopenia.

Does MOTS-c affect cancer risk?

A 2024 study in Advanced Science found MOTS-c suppresses ovarian cancer progression in a specific lab model, via a USP7-LARS1 mechanism. That's one cancer type and one mechanism, not a general anti-cancer or cancer-safety claim, and there's no long-term human data on MOTS-c and cancer risk at all.

What organs has MOTS-c been studied in besides muscle and fat?

A wide range in animal and cell models: lungs (ischemia-reperfusion injury, pulmonary fibrosis, allergic asthma), liver (diabetic fibrosis, hepatitis B defense), bone and cartilage (osteoarthritis, bone metabolism), and even soft tissue transplant survival. All are preclinical findings from 2023 to 2026, none confirmed in humans.

Why hasn't anyone run a human trial on MOTS-c yet?

Mainly cost and regulatory status. MOTS-c isn't FDA-approved, so no company has funded the IND and Phase 1-3 pipeline needed for trusted human data. Running such a trial costs millions of dollars; without patent protection guaranteeing a return, there's little commercial incentive to fund one.

Is MOTS-c legal to buy?

It depends on the source and its compounding status. Compounding pharmacies can only use substances on FDA's 503A or 503B bulk drug lists (21 CFR 216.23, 216.24), or under 21 U.S.C. 353a. Research-chemical sellers operate outside this framework entirely. Check FDA's current bulk substances page before assuming any source is compliant.

Does MOTS-c reduce inflammation or oxidative stress?

Multiple animal and cell studies point to an antioxidant mechanism, often through the Nrf2 pathway, showing up in lung injury, osteoarthritis, and asthma models between 2023 and 2025. This is a consistent mechanistic thread across organ systems in preclinical work, but it hasn't been measured in a human trial.

What's the difference between MOTS-c mechanism studies and efficacy studies?

Mechanism studies (like the 2018 Cell Metabolism paper on nuclear translocation) show how MOTS-c works inside a cell. Efficacy studies would show whether giving MOTS-c to a person improves a real health outcome. MOTS-c has plenty of the former in animals and cells and none of the latter in humans.

Should researchers take MOTS-c seriously despite the lack of human data?

Yes, as a research question. The mechanistic consistency across independent labs and organ systems, especially the recurring Nrf2 antioxidant signaling, is a genuine reason to fund human safety and dosing studies. Taking it seriously as a personal-use decision today is a separate matter, since the human safety and efficacy data simply doesn't exist yet.

Sources

1. PubMed, Frontiers in Endocrinology 2023 (PMID 36761202): MOTS-c is described as a promising mitochondrial-derived peptide for therapeutic exploitation
2. PubMed, Cell Metabolism 2015 (PMID 25738459): MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in mice
3. PubMed, Cell Metabolism 2018 (PMID 29983246): MOTS-c translocates to the nucleus to regulate nuclear gene expression under metabolic stress
4. PubMed, BioEssays 2019 (PMID 31378979): MOTS-c functions as a mitochondrial-encoded regulator of the nucleus
5. PubMed, Diabetes & Metabolism Journal 2022 (PMID 35656563): MOTS-c rises with exercise and relates to mitohormesis pathways
6. PubMed, Biochimica et Biophysica Acta 2021 (PMID 34520826): Review of mitochondrial-derived peptides and their relationship to exercise
7. PubMed, Pharmacological Research 2022 (PMID 34798268): MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes model
8. PubMed, Metabolites 2023 (PMID 36677050): MOTS-c functionally prevents metabolic disorders in preclinical models
9. PubMed, Diabetes & Metabolism Journal 2023 (PMID 36824008): Review connecting MOTS-c to diabetes and aging-related disease mechanisms
10. PubMed, Experimental & Molecular Medicine 2025 (PMID 40855115): MOTS-c prevents pancreatic islet cell senescence to delay diabetes onset in a model system
11. PubMed, Cardiovascular Drugs and Therapy 2025 (PMID 40172798): Review questioning whether MOTS-c is a therapeutic molecule for diabetic cardiomyopathy
12. PubMed, Scientific Reports 2025 (PMID 40425777): MOTS-c mimics exercise effects to combat diabetic liver fibrosis in an animal model
13. PubMed, iScience 2024 (PMID 39559755): MOTS-c modulates skeletal muscle function by binding and activating CK2
14. PubMed, Peptides 2022 (PMID 35842023): MOTS-c promotes muscle differentiation in vitro
15. PubMed, American Journal of Physiology 2021 (PMID 33554779): MOTS-c reduces myostatin and muscle atrophy signaling
16. PubMed, American Journal of Physiology 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration
17. PubMed, Sports Medicine 2026 (PMID 41966639): Review of safety and efficacy of approved and unapproved peptide therapies for musculoskeletal and athletic use
18. PubMed, Advanced Science 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression via a USP7-LARS1 mechanism in a lab model
19. PubMed, Rejuvenation Research 2018 (PMID 30058454): Some mitochondrial-derived peptides can exacerbate senescence pathways in certain contexts
20. PubMed, Redox Biology 2025 (PMID 40403491): MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation
21. PubMed, European Journal of Pharmacology 2023 (PMID 37290680): MOTS-c suppresses ferroptosis and reduces acute lung injury after myocardial ischemia reperfusion
22. PubMed, Mitochondrion 2023 (PMID 37307934): MOTS-c identified as a potential anti-pulmonary fibrosis factor derived by mitochondria
23. PubMed, International Immunopharmacology 2025 (PMID 40472776): MOTS-c attenuates airway barrier dysfunction in an allergic asthma model via Nrf2 pathway
24. PubMed, Gut 2024 (PMID 37788894): MOTS-c contributes to antiviral defense during hepatitis B infection via mitochondrial remodeling
25. PubMed, American Journal of Respiratory Cell and Molecular Biology 2025 (PMID 40035775): MOTS-c promotes glycolysis via AMPK-HIF-1a-PFKFB3 pathway to reduce cardiopulmonary bypass lung injury
26. PubMed, Frontiers in Physiology 2023 (PMID 37200834): Review of MOTS-c's role in the regulation of bone metabolism
27. PubMed, Free Radical Biology & Medicine 2025 (PMID 41043625): MOTS-c attenuates mitochondrial dysfunction, pyroptosis, and cartilage degradation in an osteoarthritis model via Nrf2
28. PubMed, Materials Today Bio 2025 (PMID 40510834): MOTS-c-modified peptide hydrogels enhance stem cell activity relevant to intervertebral disc degeneration
29. PubMed, Theranostics 2024 (PMID 39267782): MOTS-c participates in plasma membrane repair by facilitating TRIM72 translocation to the membrane
30. PubMed, Autophagy 2026 (PMID 42153537): MOTS-c ameliorates lysosomal membrane permeability and improves soft tissue transplant survival in an animal model
31. FDA, Drugs@FDA database: MOTS-c does not appear as an FDA-approved drug product
32. eCFR, 21 CFR 216.23 (503A Bulks List): Defines the bulk drug substances list permitted for 503A pharmacy compounding
33. eCFR, 21 CFR 216.24 (503B Bulks List): Defines the bulk drug substances list permitted for 503B outsourcing facility compounding
34. Cornell LII, 21 U.S.C. 353a: Sets statutory conditions under which pharmacy compounding is permitted
35. FDA, bulk drug substances nominated for compounding (current list): FDA maintains a current list of bulk substances nominated for 503A compounding consideration
36. FDA, bulk drug substances used in compounding under section 503A: FDA's authoritative page for checking the current regulatory status of bulk compounding substances